Nephrology specialists Carla Nester, MD, and Andrew Bomback, MD, delve into the rare and difficult-to-diagnose disease state of C3 glomerulopathy, a membranoproliferative form of glomerulonephritis. Recent guideline updates and recommended clinical management strategies for the treatment of glomerular disease are reviewed. In addition, the specific pathophysiology, clinical features and diagnosis of C3 glomerulopathy are discussed, as well as the global patient burden of disease and concomitant disease states caused by complement dysregulation. Insight into the historical management of C3 glomerulopathy and targeted therapies currently undergoing evaluation in late clinical trials are provided. Finally, patient resources, supportive measures and clinical perspective on the future of C3 glomerulopathy management are discussed by the faculty.
This program is also available as a podcast. You may download it here: https://anchor.fm/c3-glomerulopathy
Course Credit:
1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour
1 Pharmacology Hour
Dates:
Opens: 2022-12-15
Closes: 2023-12-15
Target Audience:
This activity is intended for nephrologists, nephrology physician associates/physician assistants and nurse practitioners, primary care physicians, pediatricians, surgeons who specialize in organ transplants, and other healthcare professionals who may be involved in diagnosis and treatment of patients with C3 glomerulopathy (C3G).
This activity is supported by an educational grant from Novartis.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 contact hour, including 1 pharmacology hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
Heather Jimenez, MSN, FNP-C (Nurse Reviewer)No significant relationships to disclose.
Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.
Laura Schmidt, PharmD (Medical Writer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Andrew S. Bomback, MD, MPH
Associate Professor of Medicine
Director of Clinical Research, Division of Nephrology
Columbia University Irving Medical Center
New York, New York -
Carla M. Nester, MD, MSA
Jean E. Robillard MD Endowed Chair in Pediatric Nephrology
Director, Division of Pediatric Nephrology, Dialysis and Transplantation
Associate Director, Molecular Otolaryngology and Renal Research Laboratory
University of Iowa Stead Family Children’s Hospital
Iowa City, Iowa
Presenting Faculty
Downloads
Learning Objectives
- Discuss recent guideline recommendations on glomerular disease management
- Describe the epidemiology and pathophysiology of C3G
- Identify the appropriate imaging and testing for diagnosis of C3G
- Construct treatment plans for patients diagnosed with C3G
- Describe the safety and efficacy of targeted therapies undergoing late-phase clinical trial evaluation in patients with C3G
Faculty Disclosures
Andrew S. Bomback, MD, MPH
Consultant: Achillion, Alexion, Apellis, Catalyst, ChemoCentryx, Novartis, Silence, Visterra, Q32
Carla M. Nester, MD, MSA
Advisory Board: Apellis, BioCryst, Novartis
Data Monitoring Safety Board: Kira
Research Support: Apellis, BioCryst, ChemoCentryx, Novartis, Retrophin